Table 1.
Potential Therapeutic Drugs and Their Targets Currently Under Trial Against COVID-19
| S. No. | Drug | Target | Action | Disease | Ongoing Clinical Trial | References |
|---|---|---|---|---|---|---|
| 1 | Niclosamide | MUC5AC | Inhibitor | Tapeworm infection | COVID-19 (Phase 2) | 111,112 |
| 2 | Tofacitinib | JAK | Inhibitor | Rheumatoid arthritis | COVID-19 (Phase 2) | 113,114 |
| 3 | Infliximab | TNF-alpha | Inhibitor | Rheumatoid arthritis, Ankylosing spondylitis | COVID-19 (Phase 2) | 115,116 |
| 4 | Tocilizumab | IL-6 | Inhibitor | Cytokine Release Syndrome (CRS) | COVID-19 (Phase 3) | 117,118 |
| 5 | Secukinumab | IL-17 | Inhibitor | Psoriasis | COVID-19 (Phase 2) | 119,120 |
| 6 | Canakinumab | IL-1 beta | Inhibitor | Muckle-Wells syndrome and TNF receptor associated periodic syndrome | COVID-19 (Phase 3) | 121,122 |